Niba Labs specializes in advanced molecular biology techniques, particularly focusing on digital PCR (dPCR) and enzyme-linked immunosorbent assays (ELISA) for the quantification and characterization of viral vectors, including adeno-associated viruses (AAV) and lentiviral vectors (LV). Their proprietary NibaPlex® technology enhances the capabilities of multiplex dPCR assays, allowing for the comprehensive quantification of complete genome populations within AAV products. This innovative approach not only improves the accuracy of vector genome integrity assessments but also correlates well with biopotency results, providing critical insights for process development and optimization in gene therapy applications.

In addition to their dPCR services, Niba Labs offers a range of analytical services, including the development and qualification of custom DNA/RNA extraction protocols, quantification of residual host cell DNA and plasmid DNA, and ELISA-based quantification of host cell proteins. Their expertise extends to the optimization of assays for viral particle quantification and the use of electron microscopy to visualize viral particles and impurities. Through collaborations with institutions like the National Institute of Biology, Niba Labs is committed to advancing the field of gene therapy by providing reliable and innovative analytical solutions tailored to the needs of their clients.

Slovenia

Niba Labs is well known for quantitative assays development, targeting specific regions of any kinds of nucleic acid constructs (i.e. digital PCR assays for viral vector genome quantification). Additionally, we can also develop custom advanced multiplex approaches that can help investigate sequence integrity.
Our mission is to advance analytical approaches for genome integrity evaluations.

Niba Labs

Company Details